尼塞维单抗引入时代2023/2024季节老年患者RSV感染的分子特征

IF 4.5 2区医学 Q2 IMMUNOLOGY

Journal of Infectious Diseases Pub Date : 2025-07-30 DOI:10.1093/infdis/jiaf062

Amandine Caillault, Laurent Softic, Pierre Bay, Arnaud Ly, Alexandre Soulier, Giovanna Melica, Christophe Rodriguez, Nicolas de Prost, Jean-Michel Pawlotsky, Slim Fourati

{"title":"尼塞维单抗引入时代2023/2024季节老年患者RSV感染的分子特征","authors":"Amandine Caillault, Laurent Softic, Pierre Bay, Arnaud Ly, Alexandre Soulier, Giovanna Melica, Christophe Rodriguez, Nicolas de Prost, Jean-Michel Pawlotsky, Slim Fourati","doi":"10.1093/infdis/jiaf062","DOIUrl":null,"url":null,"abstract":"Respiratory syncytial virus (RSV) can cause severe infections in elderly individuals. Nirsevimab is a novel prophylactic monoclonal antibody, widely used in infants in France during the 2023-2024 season. It may select for resistant RSV variants that, if transmitted in the community, could compromise vaccine efficacy in the elderly. In this study, we analyzed RSV full-length genomes (68% RSV-A, 32% RSV-B) from 125 patients aged >60 years during the 2023-2024 season. Genetic diversity of RSV-F site Ø was low, with no resistance-associated substitutions (RASs) detected. While no RASs were identified, ongoing monitoring is essential to prevent the emergence of resistant variants that could affect vaccine efficacy in the elderly.","PeriodicalId":50179,"journal":{"name":"Journal of Infectious Diseases","volume":" ","pages":"199-202"},"PeriodicalIF":4.5000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Molecular Characterization of Respiratory Syncytial Virus Infections in Elderly Patients During the 2023-2024 Season in the Era of Nirsevimab Introduction.\",\"authors\":\"Amandine Caillault, Laurent Softic, Pierre Bay, Arnaud Ly, Alexandre Soulier, Giovanna Melica, Christophe Rodriguez, Nicolas de Prost, Jean-Michel Pawlotsky, Slim Fourati\",\"doi\":\"10.1093/infdis/jiaf062\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Respiratory syncytial virus (RSV) can cause severe infections in elderly individuals. Nirsevimab is a novel prophylactic monoclonal antibody, widely used in infants in France during the 2023-2024 season. It may select for resistant RSV variants that, if transmitted in the community, could compromise vaccine efficacy in the elderly. In this study, we analyzed RSV full-length genomes (68% RSV-A, 32% RSV-B) from 125 patients aged >60 years during the 2023-2024 season. Genetic diversity of RSV-F site Ø was low, with no resistance-associated substitutions (RASs) detected. While no RASs were identified, ongoing monitoring is essential to prevent the emergence of resistant variants that could affect vaccine efficacy in the elderly.\",\"PeriodicalId\":50179,\"journal\":{\"name\":\"Journal of Infectious Diseases\",\"volume\":\" \",\"pages\":\"199-202\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/infdis/jiaf062\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/infdis/jiaf062","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

呼吸道合胞病毒可在老年人中引起严重感染。Nirsevimab是一种新型预防性单克隆抗体，在法国2023/2024年流感季节广泛用于婴儿。它可能会选择耐药的RSV变异，如果在社区传播，可能会影响疫苗在老年人中的效力。在这项研究中，我们分析了2023/2024季节125例患者的RSV全长基因组（68% RSV- a, 32% RSV- b）。RSV-F的遗传多样性较低，未检测到抗性相关替代（RASs）。虽然没有发现ras，但持续监测对于防止出现可能影响老年人疫苗效力的耐药变异至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Molecular Characterization of Respiratory Syncytial Virus Infections in Elderly Patients During the 2023-2024 Season in the Era of Nirsevimab Introduction.

Respiratory syncytial virus (RSV) can cause severe infections in elderly individuals. Nirsevimab is a novel prophylactic monoclonal antibody, widely used in infants in France during the 2023-2024 season. It may select for resistant RSV variants that, if transmitted in the community, could compromise vaccine efficacy in the elderly. In this study, we analyzed RSV full-length genomes (68% RSV-A, 32% RSV-B) from 125 patients aged >60 years during the 2023-2024 season. Genetic diversity of RSV-F site Ø was low, with no resistance-associated substitutions (RASs) detected. While no RASs were identified, ongoing monitoring is essential to prevent the emergence of resistant variants that could affect vaccine efficacy in the elderly.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Infectious Diseases 医学-传染病学

CiteScore

13.50

自引率

3.10%

发文量

449

审稿时长

2-4 weeks

期刊介绍： Published continuously since 1904, The Journal of Infectious Diseases (JID) is the premier global journal for original research on infectious diseases. The editors welcome Major Articles and Brief Reports describing research results on microbiology, immunology, epidemiology, and related disciplines, on the pathogenesis, diagnosis, and treatment of infectious diseases; on the microbes that cause them; and on disorders of host immune responses. JID is an official publication of the Infectious Diseases Society of America.